Table 1 Baseline characteristics (N = 234)
Total (%) | No Antibiotics (%) | Antibiotics (%) | p value | |
|---|---|---|---|---|
Age | ||||
< 65 | 110 (47) | 56 (44.4) | 54 (50) | 0.396 |
≥ 65 | 124 (53) | 70 (55.6) | 54 (50) | |
Sex | ||||
Male | 168 (71.8) | 91 (72.2) | 77 (71.8) | 0.875 |
Female | 66 (28.2) | 35 (27.8) | 31 (28.2) | |
ECOG score | ||||
0–1 | 200 (87.7) | 112 (92.6) | 88 (82.2) | 0.018 |
2–3 | 28 (12.3) | 9 (7.4) | 19 (17.8) | |
unknown | 6 | 5 | 1 | |
Diagnosis | ||||
NSCLC | 131 (56) | 71 (56.3) | 48 (55.6) | 0.903 |
Othersa | 103 (44) | 55 (43.7) | 60 (44.4) | |
Stage | ||||
III | 9 (3.8) | 6 (4.8) | 3 (2.8) | 0.511 |
IV | 225 (96.2) | 120 (95.2) | 105 (97.2) | |
Number of metastatic organ | ||||
0 or 1 | 151 (64.5) | 78 (61.9) | 73 (67.6) | 0.365 |
≥ 2 | 83 (35.5) | 48 (38.1) | 35 (32.4) | |
Number of treatment line | ||||
1st | 72 (30.8) | 45 (35.7) | 27 (25) | 0.198 |
2nd | 96 (41) | 49 (38.9) | 47 (43.5) | |
≥ 3rd | 66 (28.2) | 32 (25.4) | 34 (31.5) | |
ICI | ||||
Nivolumab | 135 (57.7) | 79 (62.7) | 56 (51.9) | 0.242 |
Pembrolizumab | 62 (26.5) | 29 (23) | 33 (30.6) | |
Othersb | 37 (15.8) | 18 (14.3) | 19 (17.6) | |
Treatment combination | ||||
ICI alone | 189 (80.8) | 97 (77) | 92 (85.2) | 0.063 |
ICI with ICI | 20 (8.5) | 10 (7.9) | 10 (9.3) | |
ICI with chemotherapy | 25 (10.7) | 19 (15.1) | 6 (5.6) | |
Clinical trial | ||||
Yes | 108 (46.2) | 72 (57.1) | 36 (33.3) | < 0.001 |
No | 126 (53.8) | 54 (42.9) | 72 (66.7) | |
Antibiotics type | ||||
No Antibiotics | 126 (53.8) | 126 | ||
Antibiotics | 108 (46.2) | Cephalosporins | 38 (35.2) | |
Fluoroquinolones | 26 (24.1) | |||
Beta-lactam/Betalactamase inhibitors | 18 (16.6) | |||
Othersc | 26 (24.1) | |||
Administration Route | ||||
Oral | 67 | 67 (62) | ||
Intravenous | 41 | 41 (38) | ||